King's College London

Research portal

Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on Daclizumab monotherapy

Research output: Contribution to journalArticlepeer-review

Elijah Edward Rhone, Peter Siu Pan Cho, Surinder S. Birring, James Galloway, Eli Silber

Original languageEnglish
Pages (from-to)25-27
JournalMultiple Sclerosis and Related Disorders
Early online date18 Dec 2017
Accepted/In press15 Dec 2017
E-pub ahead of print18 Dec 2017


King's Authors


As new immunomodulatory therapies continue to be licensed for use in Multiple Sclerosis, it is important to remain vigilant for new, unexpected associations relating to these medications. We highlight this by reporting on a case of a 45-year-old man who developed systemic, non-specific symptoms following long term use of daclizumab and was subsequently diagnosed with sarcoidosis. We go on to briefly discuss the action of daclizumab, in particular the effect it has on CD56bright natural killer cells, a cell type that has been investigated in relation to sarcoidosis.

Download statistics

No data available

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454